SKYTROFA provided a higher growth rate at week 52 in a clinical trial compared with a daily somatropin therapy*
Based on clinical data, pediatric patients treated with daily somatropin may be switched to SKYTROFA†
* In a clinical trial that compared once-weekly SKYTROFA with a daily somatropin in 161 children with pediatric GHD who previously had not been on treatment. The primary endpoint from the clinical trial was measuring annualized height velocity (AHV) at 52 weeks. AHV at 52 weeks was 11.2 cm/year for SKYTROFA versus 10.3 cm/year for a daily somatropin.
† SKYTROFA was studied in a 26-week clinical trial investigating the safety, tolerability, and efficacy of SKYTROFA administered once weekly in children with pediatric GHD. The trial included 3 children who previously had not been on treatment and 143 children previously treated with daily growth hormone therapies for ≤ 130 weeks. Safety and tolerability were the primary endpoints.
More injection-free days
SKYTROFA allows your child to enjoy more days without injections. With once-weekly SKYTROFA, children switching from daily injections enjoy up to 313 fewer injection days per year, which means up to 86% fewer injection days than with daily somatropin
SKYTROFA cartridges do not need to be refrigerated for up to 6 months.‡ Now, you and your child have more flexibility for storage
‡ Store SKYTROFA in the original package to protect from light. Do not freeze. SKYTROFA can be stored at room temperature (not to exceed 86°F [30°C]) for up to 6 months. Alternatively, SKYTROFA can be stored under refrigeration at 36°F to 46°F (2°C to 8°C) until the expiration date. If refrigerated, keep at room temperature for 15 minutes before use. Do not use SKYTROFA beyond the expiration date or 6 months after the date it was first removed from refrigeration (whichever is earlier).